Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on ...

Paris: Sanofi has announced that the AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner companies.

Shares in both companies were lower after one study met the primary goal and a second missed its main target in their drug ...

Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...

Sanofi & Regeneron announce itepekimab meet the primary endpoint in one of two COPD phase 3 studies: Paris Saturday, May 31, 2025, 10:00 Hrs [IST] The AERIFY-1 phase 3 study evalu ...

Analysts at Truist Securities admitted that the result for itepekimab, which the companies were hoping to follow their ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...

Sanofi and Regeneron Pharmaceuticals reported mixed results for two late-stage trials of an experimental respiratory drug they are jointly developing, with one study meeting the primary goal and a ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...